Still Waiting To Launch In U.S., NovaBay Sees Big Opportunity For Advanced Wound Care In Southeast Asia
This article was originally published in The Pink Sheet Daily
Executive Summary
While getting ready to launch FDA-approved wound-healing product NeutroPhase in the U.S., NovaBay also has expanded a commercialization partnership with Pioneer Pharma to add 13 Southeast Asian countries and territories to a collaboration once exclusive to China.
You may also be interested in...
NovaBay's Non-Antibiotic Anti-Infective Shows Efficacy In Impetigo Trial
NovaBay is a step closer to commercializing the first non-antibiotic for treating an infection typically treated with antibiotics, now that its topical gel yielded a 90 percent cure rate in a Phase IIa proof-of-concept trial against impetigo
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.